Thursday, June 11, 2026

pharma

BioPartners

BioPartners patent portfolio β€” 2 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

EU HQ
EMA registrant Type
Company details
Status
Public
HQ
EU
Programs
0
Drugs
0
Patents
2
Intelligence Β· Patents

BioPartners patents

2 pharmaceutical patents indexed for BioPartners. 0 expire within 24 months.

BioPartners has 2 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months β€” use filters for patent-cliff planning.

Patent portfolio

  1. WO 03105839

    VERWENDUNG VON RIBAVIRIN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN ZUSAMMENSETZUNG GEGEN BUNYAVIRIDAE

    Expires Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired
  2. CA 2470342

    GRANULAT DE RIBAVIRINE POUR LA PRODUCTION DE COMPRIMES PELLICULES

    Expires Wed Jun 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does BioPartners have?

2 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do BioPartners patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.